WE ARE GLAD YOU ARE HERE
Thoughts on the future of healthcare, including videos, interviews, whitepapers, and articles.
REDEFINING INNOVATION
Based on the best-selling book Redefining Innovation: Embracing the 80:80 Rule to Ignite Growth in the Bio-pharmaceutical Industry, this keynote explains why “not taking chances is not an option” for the healthcare and life sciences industry.
Industries in the U.S. are experiencing unprecedented levels of disruption and change and are broadening their definitions of innovation as a basis of competition, yet bio-pharmaceutical innovation remains narrowly focused on the bio-pharmaceutical product. This industry needs to rethink what innovation means to meet the modern healthcare consumer.
“I relate my personal experiences with setting up business units across the world’s largest bio-pharmaceutical companies and share anecdotes from other industry leaders to explain why – in the coming era – being 80% confident that you will only be 80% right the first time should feel normal.” – Ruchin
WHAT PEOPLE ARE SAYING ABOUT THIS BOOK?
“The biopharmaceutical industry has lagged behind in embracing the potential of rapidly evolving healthcare technology. To remain relevant, it needs to redefine its role and value proposition in the broader healthcare ecosystem. This book challenges conventional wisdom in which the traditional focus has been on the creating and launch of blockbuster drugs. The new focus can and should be around how digital health solutions may be applied in conjunction with medications to optimize care delivery and improve health outcomes.”
— DAVID RHEW, M.D. CHIEF MEDICAL OFFICER AND HEAD OF HEALTHCARE AND FITNESS, SAMSUNG ELECTRONICS AMERICA
“The 80-80 Rule creates urgency for Senior Leadership to redefine, communicate, and champion their organization’s Innovation Agenda.”
— WILLIAM FLEMING, PRESIDENT, HEALTHCARE SERVICES, HUMANA
“Overall I find this book to be a refreshing perspective from biopharma insiders who are trying to help their industry sector renew its business. It will be a great platform for meaningful dialog around the future of healthcare and the role that the biopharma industry will play.”
— ED YU, CHAIRMAN, VASCULAR CURES AND PARTNER, PWC